Aspergillus Fumigatus (Asp f 6) IgE

If you have asthma that keeps flaring or cystic fibrosis with worsening lung function, the difference between being merely sensitized to a common mold and having a damaging fungal lung complication changes how you should be treated. This test looks for an immune antibody made against one specific protein from Aspergillus fumigatus, and it is one of the more reliable ways to tell those two situations apart.

Standard mold IgE tests use a mixture of all the fungal proteins, which is sensitive but often picks up cross-reactivity to unrelated molds. A component-level test like this one zooms in on a single protein, which lets you and your doctor reason more precisely about what your immune system is actually responding to.

What Asp f 6 Actually Is

Asp f 6, short for allergen six from Aspergillus fumigatus, is a protein the mold uses to defend its own cells from oxygen damage (called manganese superoxide dismutase). When you inhale mold spores, your immune system can mistake this internal fungal protein for a threat and produce IgE antibodies (the antibody class that drives allergic reactions) against it. This test measures the amount of those antibodies in your blood.

Two things follow from this biology. First, your level reflects your immune system's reaction, not the amount of mold in your environment. Second, because similar superoxide dismutase proteins exist in many other fungi and even in human cells, the result is shaped by your broader fungal exposure history, not just Aspergillus.

The ABPA Question

Allergic bronchopulmonary aspergillosis, called ABPA, is what happens when the immune reaction to inhaled Aspergillus tips from background sensitization into ongoing airway inflammation, mucus plugging, and lung damage. It is most often seen in people who already have asthma or cystic fibrosis. Distinguishing ABPA from simple sensitization matters because ABPA usually requires treatment with steroids or antifungal drugs, while plain sensitization often does not.

This is where Asp f 6 IgE proves most useful. In a meta-analysis of asthma studies, having IgE to Asp f 4 or Asp f 6 correctly cleared roughly 99 out of 100 people who did not have ABPA, a specificity of 99.2%. In a more recent cystic fibrosis-specific meta-analysis, Asp f 6 alone reached about 97% specificity (correctly clearing 97 out of 100 people without ABPA), though it caught only about 39% of true ABPA cases. Skin test reactivity to Asp f 6 has been observed almost exclusively in people with ABPA, not in those merely sensitized.

How High It Tends to Run in ABPA

Among cystic fibrosis patients with ABPA, IgE levels against Asp f 4 and Asp f 6 ran roughly 16 to 18 times higher than in CF patients who had ABPA-like sensitization without the full syndrome. In a Chinese asthma cohort, 66.7% of ABPA patients had a positive Asp f 6 IgE, compared with only 14.8% of Aspergillus-sensitized asthma patients who did not have ABPA.

What this means for you: a high Asp f 6 IgE in someone with asthma or cystic fibrosis raises serious concern for ABPA and should prompt a fuller workup rather than reassurance. A low or negative result reduces the likelihood of ABPA but does not rule it out, especially if other markers (total IgE, eosinophils, imaging) point that direction.

Asthma Severity and Lung Function

Beyond the ABPA question, IgE sensitization to Aspergillus fumigatus has been linked to reduced lung function and more bronchiectasis (permanent widening and scarring of the airways) in moderate to severe asthma. In a pediatric study, Aspergillus-sensitized children with asthma had more severe disease and worse lung function than peers without that sensitization, even when they did not meet criteria for ABPA. Most of these studies measured whole-extract Aspergillus IgE rather than Asp f 6 specifically, so the same pattern is suggested but not directly confirmed for this component test.

Cystic Fibrosis

In cystic fibrosis, where the mold often colonizes thick airway mucus, sorting true allergic complications from chronic colonization is genuinely hard. Component testing with Asp f 4 and Asp f 6 was specifically developed for this problem. An early study reported that the combination of Asp f 4 and Asp f 6 IgE positivity identified ABPA with 100% specificity and about 90% sensitivity when distinguishing it from simple sensitization, though sensitivity in broader CF populations is lower (about 39% for Asp f 6 alone in a recent meta-analysis). A pattern of high Asp f 4 or Asp f 6 IgE alongside a total IgE above 1000 international units per milliliter strongly supports a diagnosis of classic ABPA in CF.

When Results Can Be Misleading

Asp f 6 belongs to a family of proteins shared across many fungi. That cross-reactivity is the single most important reason a high result does not automatically equal Aspergillus disease.

• Atopic dermatitis (eczema): In Japanese patients sensitized to Aspergillus, those who also had atopic dermatitis often had elevated Asp f 6 IgE driven by broad fungal cross-reactivity rather than true ABPA. If you have moderate to severe eczema, your result should be interpreted carefully.
• Other mold sensitization: Yeasts like Malassezia (which lives on normal skin) and other airborne molds carry related proteins. Heavy exposure or sensitization to these can push Asp f 6 IgE up.
• Treatment effects are limited: Unlike total IgE, which can fall about 52% with steroid treatment of ABPA, Aspergillus-specific IgE tends to barely move (mean change around +1.4% in one study, with some patients actually rising). A stable Asp f 6 IgE on treatment does not mean treatment is failing.
• Assay variability: Different labs use slightly different methods, and the same sample can give somewhat different numbers across testing platforms. Compare serial results from the same lab when possible.

Why Component Testing Beats Whole-Extract Testing

A standard Aspergillus fumigatus IgE test uses a crude mix of all the fungal proteins. That mix is highly sensitive (it catches almost everyone who reacts) but it cannot tell true Aspergillus sensitization apart from cross-reactivity with other molds. Component testing breaks the mold down into specific named proteins, each carrying different diagnostic weight. Asp f 1 and Asp f 3 have historically been considered sensitive markers most useful for confirming true Aspergillus sensitization, though newer data suggests Asp f 1 at optimized cutoffs may also reach high specificity for ABPA. Asp f 4 and Asp f 6 are uncommon in simple sensitization, so a positive result on either carries strong weight for ABPA.

In practice, this means you cannot substitute one test for the other. Whole-extract IgE answers the question 'has my immune system seen Aspergillus?' Asp f 6 IgE helps answer the more specific question 'does my reaction pattern look like the dangerous one?'

Tracking Your Trend

For most biomarkers, serial trending is more informative than any single reading, because every blood test has biological and lab variability. With Asp f 6 IgE, the picture is somewhat different. The specific component IgE tends to stay relatively stable over time, even with treatment of ABPA. This is actually useful: it means a baseline result reflects a real, durable feature of your immune system, not a passing fluctuation.

A reasonable approach is to get a baseline result alongside a total IgE, whole-extract Aspergillus IgE, and an eosinophil count. If your clinical picture is stable, repeat the panel annually. If you start treatment for ABPA or your symptoms shift, retest the whole panel at 3 to 6 months, recognizing that total IgE is the marker most likely to move with treatment, while Asp f 6 IgE may not change much.

What an Unexpected Result Should Trigger

A surprising positive Asp f 6 IgE, especially with other red flags, deserves a real workup rather than a wait-and-see. The next steps depend on the pattern of findings:

• Asp f 6 IgE positive with high total IgE and elevated eosinophils: This pattern in someone with asthma or cystic fibrosis raises serious concern for ABPA. A chest CT scan looking for bronchiectasis, mucus plugging, and infiltrates, plus a pulmonology or allergy referral, is appropriate.
• Asp f 6 IgE positive but other markers normal: Likely represents true Aspergillus sensitization without active ABPA, especially if you have asthma. Worth monitoring annually with the same panel, and worth thinking about indoor mold exposure.
• Asp f 6 IgE positive with eczema and broad mold sensitization: May reflect cross-reactivity rather than Aspergillus-specific disease. Interpret with caution and ask whether the clinical picture actually fits ABPA.
• Asp f 6 IgE negative but whole-extract Aspergillus IgE positive: Likely simple sensitization or cross-reactivity, less suggestive of ABPA. Other component tests (Asp f 1, f 2, f 3, f 4) can refine the picture.

This test sits inside a larger workup that almost always includes total IgE, whole-extract Aspergillus IgE, Aspergillus-specific IgG, eosinophil count, and chest imaging. No single value should be acted on alone.